Oncimmune Cost Of Revenue from 2010 to 2024

ONC Stock   14.75  0.05  0.34%   
Oncimmune Holdings' Cost Of Revenue is increasing over the years with slightly volatile fluctuation. Overall, Cost Of Revenue is expected to go to about 707.1 K this year. During the period from 2010 to 2024 Oncimmune Holdings Cost Of Revenue annual values regression line had geometric mean of  291,755 and mean square error of 286.8 B. View All Fundamentals
 
Cost Of Revenue  
First Reported
2013-01-31
Previous Quarter
780 K
Current Value
730 K
Quarterly Volatility
417.4 K
 
Yuan Drop
 
Covid
Check Oncimmune Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncimmune Holdings' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 2.4 M or Selling General Administrative of 474.1 K, as well as many indicators such as . Oncimmune financial statements analysis is a perfect complement when working with Oncimmune Holdings Valuation or Volatility modules.
  
This module can also supplement various Oncimmune Holdings Technical models . Check out the analysis of Oncimmune Holdings Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Oncimmune Stock

Oncimmune Holdings financial ratios help investors to determine whether Oncimmune Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncimmune with respect to the benefits of owning Oncimmune Holdings security.